Gene expression profiling by targeted RNA sequencing in pathological stage I lung adenocarcinoma with a solid component

Abstract

Solid predominant adenocarcinoma is considered an independent predictor of an unfavorable prognosis in patients with stage I lung adenocarcinoma (LUAD). Furthermore, solid minor components are related to poor prognosis in patients with stage I LUAD. Therefore, it is imperative to elucidate the molecular determinants of the malignant potential of solid components (SC). Several studies reported the gene expression profiling specific for lepidic predominant adenocarcinoma or solid predominant adenocarcinoma, however; there is no report identifying the differentially expressed genes (DEGs) between SC and acinar component (AC) within the same tumor tissue in pathological (p)-stage I LUAD patients. Materials and Methods: LUAD tissue samples containing both SC and AC were obtained from 8 patients with pstage I LUAD and each component was microdissected. Targeted RNA sequencing was performed by a highthroughput chip-based approach. Results: In total, 1272 DEGs were identified, including 677 upregulated genes and 595 downregulated genes in SC compared with AC. The most highly upregulated gene was TATA binding protein associated factor 7 (TAF7) and the most highly downregulated gene was homeobox B3 (HOXB3), which acts as a metastasis suppressor. A protein-protein interaction (PPI) network analysis of upregulated genes in SC identified ribosomal protein S27a (RPS27a) as a hub gene with the highest degree. First neighbors of RPS27a included PSMA6, which is a highly promising target for lung cancer. The subnetwork of PD-L1 had 10 first neighbors, including CMTM6, which enhances the ability of PD-L1-expressing tumor cells to inhibit T cells. The staining score for PD-L1 in SC was significantly higher than that in AC by immunohistochemistry (p = 0.001). Conclusion: Our results revealed several new DEGs and key PPI network in SC compared to AC, contributing to understanding the biological features of SC and providing therapeutic targets for early-stage LUAD with SC in the future.

FABP6 serves as a new therapeutic target in esophageal tumor

“…TAF7 may play an important role in cancer, as evidenced by a study of breast cancer that found significantly increased expression levels of TAF7 in tumor tissue, which was correlated with the invasive and metastatic potential of breast cancer [ 72 ]. Additionally, other studies have found abnormal expression of TAF7 in various types of cancer, including gliomas and lung adenocarcinomas [ 73 – 75 ]. These findings suggest that TAF7 may be involved in the development and progression of esophageal tumors and may be a potential therapeutic target.…”

SETD7 Promotes Cell Proliferation and Migration via Methylation-mediated TAF7 in Clear Cell Renal Cell Carcinoma

“…Mouse embryonic fibroblasts with TAF7 deletion halt transcription globally and stop proliferation, hinting at the importance of TAF7 for the survival and proliferation of embryonic cells 36 . In addition, some studies noted that TAF7 was frequently overexpressed in various cancers through bioinformatics analysis and experimental verification including breast cancer 24 , glioblastoma 25 , lung adenocarcinoma 37 and colorectal cancer 38 . Consistent with previous reports, our results indicated that TAF7 silencing inhibited ccRCC progression through reducing cell activity, increasing apoptosis, arresting S into G2/M cell cycle and diminishing migration, which substantiated the oncogenic capacity of TAF7 in ccRCC.…”

CMTM6 as a potential therapy target is associated with immunological tumor microenvironment and can promote migration and invasion in pancreatic adenocarcinoma

“…As a new regulator of PD-L1, CMTM6 co-localizes with the PD-L1 protein and stabilizes PD-L1 expression on the cell surface (Burr et al, 2017 ; Mezzadra et al, 2017 ). The anti-tumor response and immunological escape are caused by the stabilizing action of CMTM6 on PD-L1, which promotes PD-L1 on the tumor cell membrane and attaches to PD-1 on activated T cells (Kidokoro et al, 2020 ; Xie et al, 2019 ). Therefore, an increasing amount of research is focused on the interaction and association involving CMTM6 and PD-L1 in many cancers and even some inflammatory diseases.…”